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Conventional lung cancer therapies are associated with 
poor survival rates; therefore, new approaches such as gene 
therapy are required for treating cancer. Gene therapies for 
treating  lung  cancer  patients  can  involve  several 
approaches.  Among  these,  aerosol  gene  delivery  is  a 
potentially  more  effective  approach.  In  this  study,  Akt1 
kinase-deficient  (KD)  and  wild-type  (WT)  Akt1  were 
delivered  to  the  lungs  of  CMV-LucR-cMyc-IRES-LucF 
dual reporter mice through a nose only inhalation system 
using glucosylated polyethylenimine and naphthalene was 
administrated  to  the  mice  via  intraperitoneal  injection. 
Aerosol delivery of Akt1 WT and naphthalene treatment 
increased protein levels of downstream substrates of Akt 
signaling pathway while aerosol delivery of Akt1 KD did 
not.  Our  results  showed  that  naphthalene  affected 
extracellular signal-regulated kinase (ERK) protein levels, 
ERK-related  signaling,  and  induced  Clara  cell  injury. 
However, Clara cell injury induced by naphthalene was 
considerably  attenuated  in  mice  exposed  to  Akt1  KD. 
Furthermore, a dual luciferase activity assay showed that 
aerosol delivery of Akt1 WT and naphthalene treatment 
enhanced cap-dependent protein translation, while reduced 
cap-dependent  protein  translation  was  observed  after 
delivering Akt1 KD. These studies demonstrated that our 
aerosol delivery is compatible for in vivo gene delivery.
Keywords: aerosol delivery, Akt1, Clara cell, ERK, luciferase 
activity, naphthalene
Introduction
The ability to selectively deliver transgenes to the lung 
will facilitate the development of gene therapies for a 
variety of lung diseases including cancer. The aerosol 
delivery of genes represents a noninvasive means of 
targeting the lung periphery and possibly preventing some 
of the problems associated with intravenous delivery and 
intratracheal installation [13,14,43]. Viral and non-viral 
vectors are currently utilized for gene therapy. Viral 
vectors are mainly used because of their powerful cellular 
infection potential. Nevertheless, many factors can limit 
the use of viral vectors. Viral vectors need to be inactivated 
in order to prevent uncontrolled proliferation of the vector 
or an immune response against viral proteins. Therefore, 
non-viral vectors, such as liposomes and polycations, have 
been proposed as an alternative. Among these, 
glucosylated polyethylenimine (GPEI) has been proven to 
be a promising cationic polymeric delivery vector that can 
transfect cells in vitro as well as in vivo [18,26,41]. GPEI 
was reported to increase the hydrophilicity and gene 
transfer efficiency while having low toxicity compared to 
unsubstituted polyethylenimine (PEI) [8,18]. Therefore, 
we used GPEI as an aerosol delivery carrier for the current 
study.
Akt is an oncogene transduced by an acute transforming 
retrovirus (Akt-8) initially isolated from an AKR thymoma 
cell line [40] and subsequently found to encode a 
serine/threonine protein kinase [2]. Akt is also known as 
protein kinase B. This factor has a broad range of 
downstream targets that regulate tumor-associated cell 
processes such as cell growth, cell cycle progression, 
survival, migration, and angiogenesis [4]. The Akt 
pathway is an exciting novel target for molecular 
therapeutics as it acts as a cardinal nodal point for 310    Arash Minai-Tehrani et al.
transducing extracellular and intracellular oncogenic 
signals. Alterations of this pathway have been identified in 
a number of human malignancies [27]. Dominant negative 
alleles of Akt were reported to reduce cell survival and 
induce an apoptotic response [9,22]. Akt elevates both cell 
survival and proliferation rates. Therefore, specific 
inhibition of its downstream signaling pathway, for 
example through the expression of an Akt kinase-deficient 
(KD) mutant, can regulate other related signaling 
pathways mediated by Akt and may represent a reasonable 
therapeutic approach for treating tumors with elevated 
levels of Akt.
Most protein translation involves assembly of the 
eukaryotic initiation factor (eIF) 4F translation initiation 
complex on the 5´ cap structure. This is followed by 
recruitment of ribosomal subunits and their associated 
factors. The extracellular signal-regulated kinase (ERK)- 
MAPK and phosphatidylinositol 3-kinase (PI3K)-Akt 
pathways have been shown to play key roles in regulating 
protein translation efficiency [3,38,47]. One mechanism 
by which Akt and ERK are known to alter cell function is 
through the regulation of cap-dependent translation 
[34,37]. To measure the ratio of cap-dependent to 
cap-independent translation in this study, we used 
CMV-LucR-cMyc-IRES-LucF dual reporter mice. These 
transgenic mice express a bicistronic vector and can be 
used to measure cap-dependent versus cap-independent 
protein translation [6,41]. Using these animals, we show 
that aerosol delivery of Akt1 WT or KD using GPEI can 
alter Akt- and ERK-related signaling pathways along with 
protein translation in the lungs of naphthalene-treated 
mice. This may provide a target for treating lung disease.
Bioactivated xenobiotic naphthalene is extensively used 
for synthesizing a variety of compounds such as dyes, 
plastics, and grinding wheels, and is a pervasive 
environmental contaminant. It has been reported that 
humans are exposed to naphthalene during its production 
or usage, and by smoking cigarettes [7]. Parenteral 
administration of naphthalene was found to cause 
cytotoxity in the olfactory epithelium of rats and mice 
[31,48]. Non-ciliated or Clara cells in the distal bronchiolar 
epithelium are particularly susceptible to naphthalene 
injury in mice [31]. Naphthalene has been shown to reduce 
cell death and to affect ERK [7]. The ERK signaling 
cascade regulates proliferation, differentiation, and 
survival in multicellular organisms [16]. However, the 
molecular mechanism through which naphthalene affects 
protein translation and the ERK-Akt pathway is not well 
understood. Here we investigated whether ERK and Akt 
signaling pathways are involved in naphthalene-induced 
Clara cell injury. We were interested in determining 
whether we could attenuate Clara cell injury by altering 
ERK- and Akt-related signaling pathway in vivo through 
aerosol delivery of Akt1. Therefore, we evaluated the 
potential effects of Akt1 WT and Akt1 KD on protein 
signaling pathways and Clara cell injury in the lungs of 
naphthalene-treated mice. Our results clearly revealed that 
Clara cell injury induced by naphthalene was considerably 
attenuated in mice exposed to Akt1 KD. We also report that 
naphthalene can regulate ERK protein levels, downstream 
effectors of ERK, and cap-dependent protein translation.
Materials and Methods
Reagents and expression plasmids
Naphthalene was purchased from Sigma-Aldrich (USA). 
Anti-p70
S6K, anti-ERK, anti-eIF4E, anti-phospho-eIF4E, 
and anti-phospho-p70
S6K antibodies were obtained from 
Santa Cruz Biotechnology (USA). Anti-CC10 antibody 
was obtained from Abcam (USA). WT Akt1 and mutant 
Akt1, in which Lys
179 in the kinase domain was replaced by 
aspartate (K179A), were introduced into pCMV5. These 
constructs were generously provided by Dr. B. A. 
Hemmings (Friedrich Miescher Institute, Switzerland). 
They are referred to as Akt1 WT and Akt1 KD, 
respectively [41].
Aerosol  delivery  of  the  GPEI/DNA  complex  and 
naphthalene treatment
Six-week-old transgenic male mice (four mice/group) 
expressing the CMV-LucR-cMyc-IRES-LucF reporter 
gene [6,41] were used for this study. The mice were kept in 
our animal facility and maintained in a 12 h light/dark 
cycle at 23 ± 2
oC with a relative humidity of 50 ± 20%, and 
given food and water ad libitum. For each experiment, the 
mice were divided into five groups: an untreated control 
group, two groups that were exposed to an aerosol 
containing Akt1 WT/KD, or vector, and other two groups 
that were exposed to Akt1 WT/KD and or naphthalene 
only. All animal experiments were performed according to 
the guideline for the care and use of laboratory of Seoul 
National University, Korea.
GPEI was prepared by reacting cellobiose with PEI using 
cyanoborohydride as described previously [18,29]. The 
mice were placed in a nose-only exposure chamber 
(Dusturbo, Korea) and exposed to aerosol generated with a 
patented nebulizer (Korean patent no. 20304964) 
containing the GPEI/DNA complex solution for 30 min. 
GPEI/DNA complexes contained 1 mg Akt1 WT/KD, or 
pCMV5 (vector control) and 2.67 mg of GPEI. In brief, 1 
mg of DNA was mixed drop by drop with 2.67 mg of 
carrier in a final volume of 50 mL with slow vortexing. The 
solution was then incubated for 30 min at room 
temperature prior to aerosol delivery [41]. Two days after 
exposure to the aerosolized GPEI/DNA complexes, the 
mice were sacrificed and samples of the lung were 
recovered.
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to mice via i.p. injection. Mice received 200 mg of 
naphthalene/kg body weight; control animals received a 
comparable volume (10 mL/kg body weight) of corn oil 
alone. Mice that received aerosolized Akt1 complexes 
received naphthalene 1 day after gene delivery.
Western blot analysis and luciferase activity assay
Mouse lung samples were homogenized and then 
digested in three volume lysis buffer (Promega, USA). 
Total protein concentration was quantified with Bio-Rad 
Protein Assay reagent (Bio-Rad, USA) before the samples 
underwent electrophoresis. Equal amounts of protein 
extracts (50 μg) were loaded onto an SDS polyacrylamide 
gel. After electrophoresis, the separated proteins were 
transferred to nitrocellulose membranes (Amersham 
Pharmacia, UK). The membranes were blocked with 5% 
skimmed milk for 1 h at room temperature and then 
incubated with specific antibodies diluted 1 : 1,000 (v : v) 
in 5% skim milk for 3 h at room temperature. After 
washing three times with Tris-buffered saline, 0.1% Tween 
20 (TTBS), the membranes were incubated for 1 h with 
horseradish peroxidase-labeled secondary antibody 
(Zymed, USA) at room temperature. Antibody binding 
was visualized with a Westzol enhanced chemiluminescence 
detection kit (Intron, Korea). The bands were detected with 
an LAS-3000 imaging system (Fujifilm, Japan). For 
luciferase activity assay, Renilla and firefly luciferase 
activities were measured using the Dual-Luciferase kit 
(Promega, USA) according to manufacturer’s instructions 
as previously described [41].
Histopathology and immunohistochemistry
Lungs were removed from the dual luciferase mice. The 
left lobes were fixed in 10% neutral phosphate-buffered 
formalin overnight and embedded in paraffin. The 
paraffin-embedded tissues were cut (5 μm) and transferred 
to plus slides (Fisher Scientific, USA). For histological 
analysis, the tissue sections were deparaffinized in xylene, 
rehydrated through alcohol gradients and washed with 
distilled deionized water then stained with hematoxylin 
and eosin for light microscopy examination. For 
immunohistochemical analysis, the slides were immersed 
in xylene, rehydrated in ethanol, and washed with water. To 
quench endogenous peroxidase activity, the slides were 
immersed in 3% H2O2 for 10 min. After rinsing in 
phosphate-buffered saline (PBS), non-specific binding 
was blocked by incubating the sections in 3% bovine 
serum albumin (BSA) for 1 h at room temperature. After 
washing with PBS, the sections were incubated with the 
appropriate primary (1 : 200 dilution in BSA) antibodies 
for 3 h at room temperature, and secondary HRP- 
conjugated antibodies (1 : 50 dilution; Zymed, USA) for 1 
h at room temperature. After washing with PBS, the 
sections were incubated for 5 to 10 min at room 
temperature with 3,3´-diaminobenzidinetetrahydrochloride 
substrate (Biosesang, Korea) and then counterstained with 
1% Mayer’s hematoxylin (Dako, USA).
Statistical analysis
Results are expressed as the mean ± SE of three 
experiments. Statistical analyses were performed with 
Student’s t-test for experiments with two groups. A p-value 
< 0.05 was considered to be statistically significant. 
Quantification of the Western blot bands was performed 
using the Multi Gauge program (ver 2.02; Fujifilm, Japan).
Results
Akt1 WT and naphthalene increase the expression 
of ERK and cap-dependent protein synthesis while 
aerosol delivery of Akt1 KD does not
Our result showed that aerosol delivery of Akt1 WT 
increased protein expression of p70
S6K, p-p70
S6K, ERK 1/2 
(Fig. 1A), p-eIF4E, and eIF4E (Fig. 2A). We also observed 
increased expression of these proteins in the lungs of mice 
exposed to both Akt1 WT and naphthalene. No increases in 
eIF4E protein levels were observed in mice treated with 
naphthalene alone. However, naphthalene increased the 
protein levels of p70
S6K, ERK 1/2, and p-eIF4E. This 
compound also significantly changed the protein 
expression of p-p70
S6K. Densitometric analysis clearly 
confirmed the results of Western blotting analysis (Figs. 
1B and 2B). Immunohistochemistry analysis confirmed 
that the levels of ERK (Fig. 3), p-eIF4E (Fig. 4), and 
p-p70
S6K (Fig. 5) were elevated in treated mice compared 
to the control animals. These results showed patterns 
similar to those observed in the Western blot analysis.
To further evaluate the effects of Akt and naphthalene on 
cap-dependent and -independent protein translation, dual 
luciferase activities were measured. Our results clearly 
showed that aerosol delivery of Akt1 WT and naphthalene 
treatment increased the relative ratio of renilla/firefly 
activities (Fig. 2C). Based on these findings, we further 
analyzed the effects of aerosol delivery of Akt1 KD and 
naphthalene on the Akt and ERK signaling pathways. 
Western blot analysis indicated that aerosol delivery of 
Akt1 KD did not increase the protein levels of p70
S6K, 
p-p70
S6K, ERK 1/2 (Fig. 6A), p-eIF4E, and eIF4E (Fig. 
7A). However, expression of p70
S6K, p-p70
S6K, ERK 1/2, 
and p-eIF4E were all increased in mice exposed to 
naphthalene compared to the control. In contrast, 
decreased expression of these proteins was observed in 
mice exposed to both Akt1 KD and naphthalene compared 
to the mice exposed to naphthalene (Figs. 6A and 7A). 
Densitometric analysis clearly confirmed the results of 
Western blot analysis (Figs. 6B and 7B). In addition, 
measurement of luciferase activities showed that aerosol 
delivery of Akt1 KD decreased the relative ratio of 312    Arash Minai-Tehrani et al.
Fig. 1. Effects of Akt1 wild type (WT) and naphthalene on 
p70
S6K, p-p70
S6K, and extracellular signal-regulated kinase 
(ERK)1/2 protein expression. (A) Western blot and (B) 
densitometric analysis of p-p70
S6K, p70
S6K, and ERK1/2 
expression. Con: control, Vec: vector, Akt1: Akt1 WT was 
delivered to the mice, Na: mice that received naphthalene alone, 
Akt + Na: mice exposed to both Akt1 WT and naphthalene. Data
are presented as the mean ± SE (n = 3). *p < 0.05 indicating a 
significant difference compared to the corresponding control.
Fig. 2. Effects of Akt1 WT and naphthalene on eukaryotic 
initiation factor (eIF)4E and p-eIF4E protein expression. (A) 
Western blot and (B) densitometric analysis of eIF4E and 
p-eIF4E expression. (C) Effects of Akt1 on pulmonary luciferase
activity in the dual reporter mice. Con: control, Vec: vector, Akt:
Akt1 WT was delivered to the mice, Na: mice that received 
naphthalene only, Akt + Na: mice that were exposed to both Akt1
WT and naphthalene. Data are presented as the mean ± SE (n = 3).
*p < 0.05 indicating a significant difference compared to the 
corresponding control.
renilla/firefly activities while naphthalene increased this 
relative ratio (Fig. 7C).
Naphthalene-induced Clara cell injury is attenuated 
by the Akt1 KD mutant
To observe histopathological changes in the lungs of 
mice, histopathology examination was carried out. In the 
mice exposed to Akt1 WT, Akt1 KD, and the vector 
control, no histopathological changes were observed in the 
bronchiolar epithelial cells (Figs. 8A∼C). Histopatholgy 
examination revealed vacuolated or exfoliating Clara cells 
in the lumina of terminal bronchioles in mice exposed to 
naphthalene only (Fig. 8F). In mice exposed to both Akt1 
WT and naphthalene, Clara cells exfoliating into the 
lumina of the bronchioles were observed while the 
remaining cells were squamated (Fig. 8D). Mice exposed 
to both Akt1 KD and naphthalene had Clara cells 
exfoliating into the lumina of the bronchioles but the Clara 
cell injury induced by naphthalene was considerably 
attenuated compared to mice exposed to naphthalene only 
(Fig. 8E). Our histopathological results were further 
confirmed by CC10 immunohistochemical staining. CC10 
was used as a marker of lung injury and epithelial integrity 
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Fig. 3. Immunohistochemical staining of the lungs with 
anti-ERK antibody. (A) Control, (B) mice exposed to both Akt1 
WT and naphthalene, and (C) mice exposed to naphthalene only.
×200.
Fig. 5. Immunohistochemical staining of lungs with anti- 
p-p70
S6K antibody. (A) Control, (B) mice exposed to both Akt1 
WT and naphthalene, (C) mice exposed to naphthalene only, and
(D) mice exposed to Akt1 WT. ×200.
Fig. 4. Immunohistochemical staining of lungs with anti-p-eIF4E
antibody. (A) Control, (B) mice exposed to both Akt1 WT and 
naphthalene, (C) mice exposed to naphthalene only, and (D) mice
exposed to Akt1 WT. ×200.
Akt1 KD and naphthalene were recovered compared to the 
group with naphthalene alone.
Discussion
Understanding the molecular basis of numerous human 
diseases has facilitated the development of gene-based 
therapies. Gene therapy is defined as treating diseases by 
delivering therapeutic genetic material into specific cells to 
beneficially alter the expression of genes which are 
influencing the disease process. Viral vectors are 
associated with high transfection efficiency but their 
clinical application is limited by low DNA packaging 
capacities, difficulties with ensuring patient safety, risk of 
inducing an immune response, and risk of insertional 
mutagenesis [5,30,52]. Recently, difficulties associated 
with clinical tests using viral vectors have renewed interest 
in these vectors. On other hand, non-viral vectors such as 
peptides, liposomes, and polymers have various 
advantages over viral vectors such as low toxicity, ease of 
synthesis and low immune response. Some polymeric 
vectors such as GPEI have been found to have the highest 
transfection efficiency among non-viral gene delivery 
vectors, which can be comparable to that of viral vectors 
[12,15,20,25,42]. We have previously used GPEI, a 
cationic polymer, as an effective delivery vehicle for gene. 
Our group also has demonstrated the efficacy of aerosol 
gene delivery using GPEI by showing that aerosol delivery 
of Akt using GPEI could control Akt pathway and protein 
translation in the lungs of dual luciferase mice [41]. Based 
on those promising results, we chose to use GPEI as a 314    Arash Minai-Tehrani et al.
Fig. 6. Effects of the Akt1 KD mutant and naphthalene on p70
S6K,
p-p70
S6K, and ERK1/2 protein expression. (A) Western blot and 
(B) densitometric analysis of p-p
S6K, p70
S6K, and ERK1/2 
expression. Con: control, Vec: vector, KD: Akt1 KD was 
delivered to the mice, Na: mice that received naphthalene only, 
KD + Na: mice that were exposed to both Akt1 KD and 
naphthalene. Data are expressed as the mean ± SE (n = 3). *p < 
0.05 indicating a significant difference compared to the 
corresponding control.
Fig. 7. Effects of Akt1 KD and naphthalene on eIF4E and 
p-eIF4E protein expression. (A) Western blot and (B) 
densitometric analysis of eIF4E and p-eIF4E expression in the 
lung of the luciferase mice. (C) Effects of Akt1 on pulmonary 
luciferase activity in the dual reporter mice. Con: control, Vec: 
vector, KD: Akt1 KD was delivered to the mice, Na: mice that 
received naphthalene only, KD + Na: mice that were exposed to 
both Akt1 KD and naphthalene. Data are expressed as the mean
± SE (n = 3).
carrier for the present study.
Molecular genetic studies have led to the identification of 
different potential targets for therapeutic modalities, such 
as Akt [23]. The Akt signaling pathway has been shown to 
regulate cell proliferation and survival, and is closely 
associated with the progression of different lung diseases 
[23,33]. Elevated Akt activity has been observed in 
malignant human bronchial epithelial and Non-small-cell 
lung carcinoma (NSCLC) cells [23,24,33,39]. Therefore, 
targeting this pathway may be extremely useful in clinical 
settings, especially for treating NSCLC and other lung 
diseases in which constitutive activation of Akt frequently 
occurs. In the present study, we showed that the Akt1 KD 
construct could regulate Akt-related signaling pathway.
Airway injury and repair are involved in the pathogenesis 
of several lung diseases such as asthma, chronic 
obstructive pulmonary disease, and lung cancer. Among 
the different factors that cause lung injury, hazardous air 
pollutants exert chronic adverse effects on lung functions, 
and are reported to be partly responsible for morbidity and 
mortality in humans [10,21]. Clara cells, the non-ciliated 
cells in the epithelial lining of bronchioles, have several 
roles in the lungs. One of the main functions of Clara cells 
is to protect the bronchiolar epithelium. Naphthalene (200 
mg/kg) has been reported to cause Clara cell injury [31,51]. 
This compound is used as feedstock for variety of chemical 
industrial processes, and was found to be the most plentiful 
polycyclic aromatic hydrocarbon in cigarette smoke that Akt1 KD attenuates Clara cell injury induced by naphthalene    315
Fig. 9. Immunohistochemical staining of lungs with anti-CC10 
antibody. (A) Mice exposed to naphthalene only and (B) mice 
exposed to both Akt1 KD and naphthalene. ×200.
Fig. 8. Histopathology of the lungs. (A) Vector control, (B) mice 
exposed to Akt1 WT, (C) mice exposed to Akt1 KD, (D) mice 
exposed to both Akt1 WT and naphthalene, (E) mice exposed to
Akt1 KD and naphthalene, and (F) mice exposed to naphthalene
only. H&E stain, ×400.
selectively injures Clara cells in the conducting airways 
[10,21,32,46,50]. Clara cell injury patterns observed in the 
present study were similar to ones previously described 
[31,51]. We also showed that the Clara cell injury induced 
by naphthalene was diminished in the lungs of mice 
exposed to Akt1 KD as demonstrated by histopthological 
and CC10 immunohistochemical analyses.
Naphthalene has been reported to decrease cell death and 
induce an anti-apoptotic response. This chemical induces 
IL-8 production that has been reported to affect ERK [7]. 
ERK is a part of the MAPK family of serine/threonine 
kinases. It is activated by phosphorylation of a tyrosine- 
threonine motif and in turn phosphorylates a number of 
downstream substrates including a consensus proline- 
directed serine or threonine site. The ERK signaling 
cascade is involved in cellular proliferation, differentiation, 
and survival, and its inappropriate activity is a common 
feature of human cancers [16,28]. Thus, regulating the 
ERK cascade by introducing Akt KD may be good strategy 
for controlling protein translation and attenuating Clara 
cell injury induced by naphthalene exposure. The findings 
of our study indicated that naphthalene affected the 
downstream effectors of ERK, suggesting a role for 
ERK-related signaling pathways in Clara cell injury. 
Essential steps in protein translational control take place 
at the level of eIF4F and p70 S6 kinase. eIF4F is a complex 
whose activity involves the recognition of the RNA 5´ cap 
structure and eukaryotic translation initiation factor. eIF4E 
has been shown to contribute to the formation eIF4F 
complex. p70 S6 kinases phosphorylate the 40S ribosomal 
subunit protein S6 and activate the translation of mRNA 
containing 5´ ligopyrimidine tracts. The ERK pathway is 
involved in regulating this process by activating the eIF4E 
and p70 S6 kinases [1,11,17,44]. The results of our study 
clearly showed that naphthalene increased ERK, p70
S6K, 
p-p70
S6K, and p-eIF4E protein levels. Increased expression 
of p-p70
S6K and p-eIF4E were also observed in the lungs of 
mice exposed to both Akt1 WT and naphthalene, while 
Akt1 KD decreased the phosphorylation of p70
S6K and 
eIF4E induced by naphthalene. These finding suggested 
that the signaling pathway induced by naphthalene can be 
regulated by aerosol delivery of Akt1.
eIF4E is a target of PI3K/Akt and ERK signaling, and 
may behave as a point of convergence for these two 
pathways. PI3K signaling leads to elevated eIF4E activity 
following release from the 4E-BPs while ERK increases 
the phosphorylation of eIF4E [45,47,49]. eIF4E influences 
cancer-relevant processes such as apoptosis and 
senescence [33,34], and behaves as an oncogene alone or 
in combination with c-myc. Not surprisingly, these 
functions enable eIF4E to control protein translation 
although other eIF4E-associated activities may also be 
required [19,35,36,46].
In this study, we found that elevated ERK expression 
induced by naphthalene could partially activate p70
S6K and 
eIF4E, resulting in an increase of cap-dependent protein 
translation and damage to Clara cell. Introduction of Akt1 
WT by aerosol delivery further increased cap-dependent 316    Arash Minai-Tehrani et al.
protein translation while Akt1 KD decreased this protein 
translation, thereby reducing Clara cell injury. These 
results indicate the involvement of Akt- and ERK-related 
pathways in Clara cell injury induced by naphthalene, and 
show that alterations in ERK-related signaling pathway 
caused by Akt1 KD introduction can attenuate Clara cell 
injury induced by naphthalene.
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